Skip to main content

Edward Moreira Bahnson, PhD

Assistant Professor

Research Interests

Cardiovascular disease accounts for 2,300 deaths per day in the US, claiming as many lives as the next four leading causes combined. Current vascular interventions for severe arterial atherosclerosis have limited success due to restenosis secondary to neointimal hyperplasia and remodeling. Our interest in arterial disease drives the projects in the lab.

  • Understanding why arterial disease is more aggressive in diabetic patients, with an emphasis in understanding the redox dysfunction in the vasculature.
  • Understanding how other causes of redox dysfunction such as air pollution affect vascular surgery outcomes.
  • Developing targeted systems using nanotechnology to locally deliver redox-based therapeutics to the diseased arteries.

Research Synopsis

Cardiovascular disease accounts for 2,300 deaths per day in the US, claiming as many lives as the next four leading causes combined. Current vascular interventions for severe arterial atherosclerosis have limited success due to restenosis secondary to neointimal hyperplasia and remodeling. Diabetes mellitus (DM) represents a particular challenge, as it increases the incidence and accelerates the course of atherosclerosis. Patients with DM and metabolic syndrome have aggressive forms of vascular disease, possessing a greater likelihood of end-organ ischemia, as well as increased morbidity and mortality following vascular interventions, and requiring more revascularization procedures compared to the general population at an earlier point in time. Our interest in arterial disease drives the projects in the lab:

Understanding the difference in plaque progression and restenosis rates in the diabetic vs. non-diabetic environment. Atherosclerosis leading to CVD and PAD is a leading cause of morbidity and mortality in diabetic patients. It is paramount to gain insight into the particular diabetic milieu that so profoundly affects the progression of atherosclerotic disease and the rates of restenosis after revascularization. To study arterial disease progression we have developed a rat model that is both prone to atherosclerosis and to develop type II diabetes.

Developing a specific targeted therapy for the vasculature to normalize the redox imbalance of diseased/injured arteries. Whereas human studies using antioxidant-based therapies have for the most part not shown differences in clinical outcomes, some studies using local delivery have shown promising results in humans. Hence, the biggest challenge for successful clinical translation is the targeted delivery of the therapeutic in the right amount at the right site. Nanotechnology has the potential to revolutionize the way we treat a wide variety of pathologies. We are interested in changing the way we think about treatment via the design of peptide-based tailored nanocarriers capable of targeting specific locations and deliver a therapeutic load locally to the site of interest.”

Investigating how vascular surgery outcomes are affected by environmental factors that might disrupt redox homeostasis. It is well established that air pollution contributes to the development of cardiovascular disease and atherosclerosis. Patients with severe atherosclerotic disease generally undergo revascularization surgical procedures. We want to study how exposure to environmental stressors such as ozone, affect vascular surgical outcomes.

Publications

View complete list of publications in NCBI library

Edward Moreira Bahnson, PhD
  • Department of Pharmacology

  • Department of Surgery, Division of Vascular Surgery

  • Department of Cell Biology & Physiology

  • Center for Nanotechnology in Drug Delivery